Bristol Myers Squibb (CELG-RI) Long-Term Deferred Tax (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Long-Term Deferred Tax data on file, last reported at $5.2 billion in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $5.2 billion, up 29.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 billion (up 29.5% YoY), and the FY2025 annual result was $5.4 billion, up 26.96% from the prior year.
• Long-Term Deferred Tax slipped to $5.2 billion in Q1 2026 per CELG-RI's latest filing, from $5.4 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $5.4 billion in Q4 2025 and troughed at $1.3 billion in Q1 2023.
• A 5-year average of $3.0 billion and a median of $2.8 billion in 2023 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax slipped 7.12% in 2023, then surged 138.38% in 2024.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.3 billion in 2022, then surged by 105.95% to $2.8 billion in 2023, then surged by 53.03% to $4.2 billion in 2024, then advanced by 26.96% to $5.4 billion in 2025, then retreated by 3.76% to $5.2 billion in 2026.
• Business Quant data shows CELG-RI's Long-Term Deferred Tax at $5.2 billion in Q1 2026, $5.4 billion in Q4 2025, and $5.0 billion in Q3 2025.